82499-02-3

Basic information

• Product Name: 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE
• Synonyms: 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE
• CAS NO: 82499-02-3
• Molecular Formula: C₆H₆ClN₅
• Molecular Weight: 183.6
• Product Categories: Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Purines;PurinesHeterocyclic Building Blocks;Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 82499-02-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: 282.1°C at 760 mmHg
• Flash Point: 124.4°C
• Appearance: /
• Density: 1.76g/cm³
• Vapor Pressure: 0.00343mmHg at 25°C
• Refractive Index: 1.807
• CAS DataBase Reference: 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE(82499-02-3)
• EPA Substance Registry System: 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE(82499-02-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43-41-37/38
• Safety Statements: 36/37-39-26
• WGK Germany: 3
• Hazardous Substances Data: 82499-02-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-N-methyl-9H-purin-6-amine, also known as 6-Chloroguanine, is a chemical compound that belongs to the purine family. It is a derivative of guanine and is commonly used as a building block in the synthesis of various pharmaceuticals and nucleoside analogs. 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE is notable for its potential use in the development of antiviral and anticancer drugs, as well as its ability to inhibit key enzymes involved in DNA and RNA synthesis. Additionally, 2-Chloro-N-methyl-9H-purin-6-amine has been studied for its biological activities and potential therapeutic applications in various disease conditions.

InChI:InChI=1/C6H6ClN5/c1-8-4-3-5(10-2-9-3)12-6(7)11-4/h2-3H,1H3,(H,8,9,10,11,12)

Upstream product

• 5451-40-1 2,6 dichloropurine 
• 74-89-5 methylamine 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 1026464-95-8 2-[2-(2-chloro-6-methylamino-purin-9-yl)-ethyl]-2-ethoxycarbonyl-malonic acid diethyl ester 
• 262863-49-0 9-bis(2-dibenzylphosphatoethylamino)-acetyl-2-chloro-6-methylamino-purine 
• 264611-17-8 1,5-anhydro-2-(2-chloro-N⁶-methyladenin-9-yl)-2,3-dideoxy-D-arabino-hexitol-4,6-(dibenzyl phosphate) 
• 1027657-72-2 2-[2-(2-chloro-6-methylamino-purin-9-yl)-ethyl]-propane-1,3-bisoxy(dibenzylphosphate) 
• 262863-50-3 tetramethyl (2-chloro-6-methylamino-purin-9-yl)-acetaminophenyl-3',5'-bis(methylphosphonate) 

Relevant articles and documents

Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors

The aminobenzamide is selective to class I histone deacetylases (HDACs) and displays unique tight-binding/slow-off HDAC-binding mechanism. Herein, we report a series of 9-substituted purine aminobenzamides that selectively inhibit class I HDACs. The activities in vitro showed compound 9d exhibited 12 folds more potent than MS-275 against HDAC1 isoform and showed excellent inhibitory activity on cancer cells, including HCT-116, MDA-MB-231, K562 cell lines. The metabolic stability of 9d was much better than that of the well-known HDAC inhibitor SAHA. Pulse exposure test of western blot assay demonstrated that 9a, 9d induced histone acetylation in a similar manner to MS-275. Further biological validation demonstrated that 9d prevented cell transition from G1 phase to S phase by reducing Cyclin D1, CDK2 and lifting p21, induced early apoptosis by upregulating BAX and downregulating Bcl-2 in HCT-116 cells.

Syntheses and biological evaluation of novel hydroxamic acid derivatives containing purine moiety as histone deacetylase inhibitors

The novel hydroxamates containing purine scaffold were designed, synthesized and screened for their biological activities as histone deacetylase (HDAC) inhibitors. Some of them exhibited excellent acti-HDACs activities and antiproliferative activities, th

LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME

Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.